Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average of $0.75
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average of $0.75
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Rating)'s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.75 and traded as low as $0.71. Northwest Biotherapeutics shares last traded at $0.73, with a volume of 1,293,028 shares trading hands.
西北生物治療學公司（OTCMKTS：NWBO — 獲取評級）的股價在周四交易過程中低於 200 天移動平均線。該股票的 200 天移動平均線為 0.75 美元，交易價格低至 0.71 美元。西北生物治療股票最後交易價為 0.73 美元，交易量為 1,293,028 股。
Northwest Biotherapeutics Stock Down 1.2 %
西北生物治療庫存下降 1.2%
The stock has a 50 day moving average of $0.82 and a two-hundred day moving average of $0.75.
該股有一個 50 日移動平均線 0.82 美元和 200 日移動平均線 0.75 美元。
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Rating) last posted its earnings results on Wednesday, November 9th. The biotechnology company reported ($0.03) EPS for the quarter. The business had revenue of $0.21 million during the quarter.
西北生物治療學 (OTCMKTS: NWBO — 獲取評級) 最後公佈了其盈利業績週三, 11 月 9 日.該生物技術公司報告了本季度每股盈利（0.03 美元）。該業務在本季度的收入為 0.21 萬美元。
About Northwest Biotherapeutics
關於西北生物治療學
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
西北生物治療學公司是一家生物技術公司，在美國和國際上開發了針對癌症的個性化免疫療法。該公司基於 DCVax 開發產品，這是一種平台技術，該技術使用活化樹突狀細胞調動患者自身的免疫系統來攻擊癌症。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Northwest Biotherapeutics (NWBO)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費索取西北生物治療研究報告
- 市場節拍週的回顧 — 1/23-1/27
- 為什麼清醒在一天內飆升近 100％
- 乘坐這些鐵路股票以獲得增長和收入
- ASML 今年看到籌碼需求上升，提高了銷售觀點
- KLA 公司：陷入困境的半市場中的實力
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收西北生物治療日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關西北生物治療及相關公司的最新新聞和分析師評級的簡要每日摘要。